Aldeyra Therapeutics (NASDAQ:ALDX) Move as Institutional Investors’ Sentiment Worsens

Sentiment for Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics (NASDAQ:ALDX) institutional sentiment decreased to 1.5 in Q2 2019. Its down -0.13, from 1.63 in 2019Q1. The ratio has dropped, as 42 hedge funds increased and started new positions, while 28 trimmed and sold equity positions in Aldeyra Therapeutics. The hedge funds in our partner’s database now possess: 15.81 million shares, up from 15.47 million shares in 2019Q1. Also, the number of hedge funds holding Aldeyra Therapeutics in their top 10 positions was flat from 1 to 1 for the same number . Sold All: 15 Reduced: 13 Increased: 26 New Position: 16.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $159.68 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

The stock decreased 1.03% or $0.06 during the last trading session, reaching $5.79. About 233,848 shares traded. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has declined 19.41% since September 13, 2018 and is downtrending. It has underperformed by 19.41% the S&P500.

Analysts await Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to report earnings on November, 13. They expect $-0.52 EPS, 0.00 % or $0.00 from last year’s $-0.52 per share. After $-0.49 actual EPS reported by Aldeyra Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 6.12 % negative EPS growth.

Knoll Capital Management Lp holds 2.6% of its portfolio in Aldeyra Therapeutics, Inc. for 529,390 shares. 683 Capital Management Llc owns 2.13 million shares or 1.16% of their US portfolio. Moreover, Sphera Funds Management Ltd. has 0.88% invested in the company for 1.07 million shares. The New York-based Perceptive Advisors Llc has invested 0.42% in the stock. Dafna Capital Management Llc, a California-based fund reported 50,000 shares.

Since January 1, 0001, it had 5 buys, and 0 insider sales for $263,430 activity.

More notable recent Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) news were published by: Nasdaq.com which released: “Mid-Morning Market Update: Markets Open Higher; Carnival Issues Weak Profit Outlook – Nasdaq” on March 26, 2019, also Benzinga.com with their article: “80 Biggest Movers From Yesterday – Benzinga” published on September 11, 2019, Seekingalpha.com published: “Aldeyra buys Helio Vision for up to $25M in all-stock deal – Seeking Alpha” on January 29, 2019. More interesting news about Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) were released by: Benzinga.com and their article: “The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin’s Parkinson’s Add-On Therapy Approved – Benzinga” published on August 28, 2019 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission – Benzinga” with publication date: August 16, 2019.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.